Part-Time
Speech Language Pathologist
Part-Time SLP
Posted on 9/11/2025
BrightSpring Health Services
10,001+ employees
Home-based and community health services, pharmacy
Compensation Overview
$50/hr
San Bernardino, CA, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Minimum of Master’s Degree in Speech Language Pathology from a college or university with accredited Speech Language Pathology program
- Current, unrestricted license as an Speech Language Pathologist by state in which practicing
- Current Basic Life Support or cardiopulmonary resuscitation certification in accordance state regulations
- A minimum of one year’s work experience as a Speech Language Pathologist
- Demonstrates knowledge of rehabilitation techniques related to complex neurological injury required
- Communicates effectively and professionally in verbal and written interactions
- Demonstrates strong organization skills and attention to detail
- Performs the evaluation and treatment of patients with speech, language and cognitive disorders
- Reviews patient records for current diagnosis, past medical history, precautions & contraindications
- Establishes measurable goals and develops treatment plan to move the patient toward his or her maximum level of speech, language and cognitive abilities with a focus on selecting goals that compliment/supplement the goals written by the BCBA. Manage goals and data tracking in Catalyst application
- Trains ABA staff on how to accurately and effectively support patient specific SLP goals
- Regularly re-assesses effectiveness of treatment plan, progress of patient toward goals and the need for modifying goals or treatment
- Communicates patient’s needs and progress to the treatment team, school, outside service provider, person receiving services, family members, as applicable
- Maintains and submits evaluation, treatment, discharge and billing documentation in the format and time-lines required by the Company, facility, funding source, local, state and federal regulations
- Adheres to standards of the Company's Code of Business Conduct, policies, Health Insurance Portability Accountability Act, Corporate Compliance programs, appropriate professional practice standards and applicable state/federal laws
- Attends, participates in and/or conducts internal staff development programs and meetings; obtains continuing education as required by company policy and regulations; maintains and enhances clinical practice skills
- Communicates weekly updates to the BCBA regarding student's SLP goals, progress, barriers, etc
- Manages scheduling for all SLP therapy sessions and communicates these times to the clinic staff
BrightSpring Health Services provides home and community-based health care through two main operations: Pharmacy and Provider. In Pharmacy, it offers services for patients with complex and chronic conditions, including specialty, infusion, and community pharmacy solutions. In Provider, it delivers home health, behavioral health, hospice care, and services for intellectual and developmental disabilities. The company uses an integrated care model that connects pharmacy services with in-home care across its network to support patients, families, and managed care organizations. Revenue comes from reimbursed services paid by Medicare, Medicaid, and private insurers. Its goal is to coordinate ongoing, in-home and community-based care across a continuum—from pharmacy support to direct care—ensuring coordinated, patient-centered services for individuals with complex or chronic needs.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Louisville, Kentucky
Founded
1974
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $3.61B, up 26%, raising full-year guidance to $14.98B.
- Amedisys and LHC acquisitions add 107 locations, contributing $30M EBITDA in 2026.
- Sevita sale yields $811M cash for debt reduction and $2B M&A through 2028.
What critics are saying
- Money Message ransomware stole 2M records including SSNs in March 2023 breach.
- DOJ fined ResCare in October 2019 for fake Medicaid revaluations from 2009-2014.
- Pomerantz investigates securities fraud by BrightSpring officers as of 2026.
What makes BrightSpring Health Services unique
- BrightSpring integrates specialty pharmacy with home health for complex chronic care patients.
- PharMerica dispenses 40 million prescriptions annually to 4 million patients.
- Provider services target intellectual disabilities via home-based behavioral health.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
BrightSpring Health Services announced the resignation of Robert Barnes as President of ResCare Community Living on 30 March 2026, stating it was not due to any disagreement over operations or policies. The company's shares rose 5.2% following upbeat analyst reports from its investor day. Management unveiled ambitious long-term organic EBITDA growth targets of 15% to 20% annually through 2028, alongside AI-driven efficiency plans for its home and community-based care platform. The narrative projects $16.8 billion in revenue and $361.8 million in earnings by 2028, requiring 10.1% yearly revenue growth. Investors remain focused on whether BrightSpring can balance acquisition-driven expansion and technology investment whilst managing its substantial debt load and regulatory exposure.
BrightSpring Health Services has seen its stock price surge 43.1% over the past six months to $42.32 per share, driven by strong quarterly results. The healthcare services company, founded in 1974, offers home health care, hospice, neuro-rehabilitation and pharmacy services. BrightSpring's revenue grew at an 18.3% compound annual growth rate over the past five years, outpacing the healthcare sector average. Analysts forecast 15% revenue growth over the next 12 months, though this represents a deceleration from its recent 20.9% annual rate. However, the company's five-year average return on invested capital of 4.9% falls below the typical cost of capital for healthcare firms, suggesting historically mediocre capital efficiency. The stock currently trades at 27.7× forward price-to-earnings ratio.
BrightSpring Health Services has raised questions about its valuation after trading at 24.5 times forward earnings following strong 2025 performance. The company reported fourth-quarter revenue of $3.55 billion, up 29.3% year-over-year, with adjusted EBITDA rising 40.7% to $184 million. For 2026, management guided revenue between $14.45 billion and $15 billion, representing 11.9% to 16.2% growth, whilst adjusted EBITDA is expected to grow faster at 23% to 28%, indicating margin expansion. However, the company faces approximately $600 million in revenue headwinds from Inflation Reduction Act impacts and brand-to-generic conversions. The valuation hinges on whether BrightSpring can deliver sequential profitability improvements throughout the year despite policy and product-mix pressures affecting headline revenue growth.
BrightSpring Health Services led senior health stocks in Q4 earnings, reporting revenues of $3.55 billion, up 16.3% year on year and beating analyst expectations by 5%. The company delivered strong full-year EBITDA guidance. In contrast, Chemed posted the weakest performance, with revenues of $639.3 million falling 3% short of expectations. The company missed both revenue and full-year EPS guidance estimates, sending shares down 19.2% to $377.07. The seven senior health, home health and hospice stocks tracked reported slower Q4 results overall, with revenues beating consensus estimates by just 1.1%. Share prices have declined an average of 9.6% since earnings releases. The sector faces headwinds from labour shortages and wage inflation whilst benefiting from an ageing population and growing preference for in-home care.
BrightSpring Health Services outlined its growth strategy at an investor day, highlighting a shift towards core home-and-community clinical services. The company's planned community-living divestiture will close soon to boost cash flow and support integrated care initiatives. BrightSpring reported significant deleveraging from approximately 4.5x post-IPO to 2.99x (2.6x pro forma), with leverage expected to fall below 2x in 2026. The company reiterated 2026 guidance of $14.45–$15.0 billion revenue and $760–$790 million adjusted EBITDA, whilst targeting 15–20% organic adjusted EBITDA compound annual growth for 2026–2028. The healthcare services provider has at least $2 billion available for acquisitions through 2028. Its operations include dispensing over 40 million prescriptions annually through PharMerica, serving more than 4 million patients, with recent branch integrations expected to add approximately $30 million of EBITDA.